Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.58)
# 2,725
Out of 5,182 analysts
159
Total ratings
57%
Success rate
-1.55%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELV Elevance Health | Maintains: In-Line | $345 → $360 | $356.13 | +1.09% | 2 | Apr 23, 2026 | |
| TDOC Teladoc Health | Maintains: In-Line | $5 → $6 | $5.85 | +2.56% | 8 | Apr 8, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $26 | $24.41 | +6.51% | 6 | Apr 8, 2026 | |
| OMDA Omada Health | Maintains: Outperform | $20 → $15 | $14.72 | +1.90% | 2 | Apr 8, 2026 | |
| NVST Envista Holdings | Maintains: Outperform | $32 → $30 | $26.77 | +12.07% | 5 | Apr 8, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $280 → $300 | $263.43 | +13.88% | 8 | Apr 8, 2026 | |
| IQV IQVIA Holdings | Maintains: Outperform | $225 → $185 | $163.84 | +12.92% | 8 | Apr 8, 2026 | |
| HSIC Henry Schein | Maintains: Outperform | $100 → $90 | $77.20 | +16.58% | 4 | Apr 8, 2026 | |
| HNGE Hinge Health | Maintains: Outperform | $50 → $45 | $45.03 | -0.07% | 4 | Apr 8, 2026 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $25 → $14 | $10.60 | +32.08% | 12 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $240 | $202.34 | +18.61% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,000 → $950 | $828.32 | +14.69% | 8 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $220 → $210 | $196.63 | +6.80% | 6 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $30 → $25 | $24.66 | +1.38% | 11 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $12 → $15 | $11.96 | +25.42% | 9 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $55 | $45.23 | +21.60% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $27 | $25.70 | +5.06% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $200 | $184.70 | +8.28% | 16 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $78.36 | +21.24% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.37 | +118.98% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $125 → $75 | $25.32 | +196.21% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $1.17 | +2,143.59% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.76 | +752.27% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $0.92 | +1,098.39% | 2 | Jan 4, 2022 |
Elevance Health
Apr 23, 2026
Maintains: In-Line
Price Target: $345 → $360
Current: $356.13
Upside: +1.09%
Teladoc Health
Apr 8, 2026
Maintains: In-Line
Price Target: $5 → $6
Current: $5.85
Upside: +2.56%
Privia Health Group
Apr 8, 2026
Maintains: Outperform
Price Target: $30 → $26
Current: $24.41
Upside: +6.51%
Omada Health
Apr 8, 2026
Maintains: Outperform
Price Target: $20 → $15
Current: $14.72
Upside: +1.90%
Envista Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $32 → $30
Current: $26.77
Upside: +12.07%
Labcorp Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $280 → $300
Current: $263.43
Upside: +13.88%
IQVIA Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $225 → $185
Current: $163.84
Upside: +12.92%
Henry Schein
Apr 8, 2026
Maintains: Outperform
Price Target: $100 → $90
Current: $77.20
Upside: +16.58%
Hinge Health
Apr 8, 2026
Maintains: Outperform
Price Target: $50 → $45
Current: $45.03
Upside: -0.07%
Fortrea Holdings
Apr 8, 2026
Maintains: Outperform
Price Target: $25 → $14
Current: $10.60
Upside: +32.08%
Apr 8, 2026
Maintains: Outperform
Price Target: $260 → $240
Current: $202.34
Upside: +18.61%
Apr 8, 2026
Maintains: Outperform
Price Target: $1,000 → $950
Current: $828.32
Upside: +14.69%
Apr 8, 2026
Maintains: In-Line
Price Target: $220 → $210
Current: $196.63
Upside: +6.80%
Apr 8, 2026
Downgrades: In-Line
Price Target: $30 → $25
Current: $24.66
Upside: +1.38%
Feb 27, 2026
Maintains: In-Line
Price Target: $12 → $15
Current: $11.96
Upside: +25.42%
Feb 26, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $45.23
Upside: +21.60%
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $25.70
Upside: +5.06%
Feb 5, 2026
Maintains: Outperform
Price Target: $180 → $200
Current: $184.70
Upside: +8.28%
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $78.36
Upside: +21.24%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.37
Upside: +118.98%
Jul 9, 2025
Maintains: In-Line
Price Target: $125 → $75
Current: $25.32
Upside: +196.21%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $1.17
Upside: +2,143.59%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.76
Upside: +752.27%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $0.92
Upside: +1,098.39%